GW Pharmaceuticals Plc

GW Pharmaceuticals Plc

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
Company Details
Drug Manufacturers - Major
Full time employees
United Kingdom

GW Pharmaceuticals Plc News

21 Mar

How Cannabis is Going 'Greener'

HENDERSON, NV / ACCESSWIRE / March 21, 2019 / The electricity consumption of cannabis grow houses is staggering when compared to business and residential use. In 2015, the average electricity consumption...

20 Mar

GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should Know

GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $170.27, moving +1.28% from the previous trading session.

18 Mar

2 Hemp Stocks for Investors Looking for Something Different

in early November, writing this: "Investors need to risk a close below $130 to trade GWPH from the long side. Looking back at the price action since the beginning of November, chart below, we can see...

18 Mar

GW Pharma announces sale of priority review voucher for $105 million

GW Pharmaceuticals Plc said Monday it is selling its Rare Pediatric Disease Priority Review Voucher for $105 million. The company, which was the first to receive U.S. Food and Drug Administration approval...

18 Mar

GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd....

18 Mar

GW Pharma sells Priority Review Voucher for $105M

GW Pharmaceuticals (NASDAQ: GWPH ) has agreed to sel l its Rare Pediatric Disease Priority Review Voucher that it received when Epidiolex was approved in the U.S. for rare types of epilepsy for $105M...

16 Mar

Better Marijuana Stock: Aurora Cannabis vs. GW Pharmaceuticals

Which stock wins in a matchup between a top Canadian marijuana producer and a leading cannabinoid drugmaker?

15 Mar

Moving Average Crossover Alert: GW Pharmaceuticals

GW Pharmaceuticals plc (GWPH) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

14 Mar

Three of the Influential Health and Wellness Cannabis Companies

Multi-billion-dollar industries are already being uprooted by cannabis, including beverages, alcohol, beer, sports drinks, pharmaceuticals, tobacco, and the $3.2 trillion wellness industry, as the cultural...

12 Mar

Top Cannabis Plays-THC Therapeutics, Inc

HENDERSON, NV / ACCESSWIRE / March 12, 2019 / Year to date, the Global Cannabis Stock Index is up almost 50% in less than three months. It's safe to say investors are bullish on the cannabis. Here are...

Load more

About GW Pharmaceuticals Plc

GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.

GW has developed an oral formulation of purified cannabidiol (CBD), approved as Epidiolex® in the U.S. by the U.S. Food and Drug Administration (FDA) for seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome, two rare and severe early-onset, drug-resistant epilepsy syndromes. This is the first cannabis plant-derived medicine ever approved by the FDA and it has been rescheduled by the U.S. DEA to a schedule V. The medicine was launched in the US as a prescription medicine by our US operating subsidiary, Greenwich Biosciences Inc., on November 1, 2018. GW has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with an expected decision date in early 2019.

GW successfully developed the world’s first prescription medicine derived from the cannabis plant, called Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US), which is now approved in over 25 countries outside of the US for the treatment of spasticity due to multiple sclerosis. GW continues to research and develop Sativex.

The company has a deep pipeline of additional clinical stage cannabinoid product candidates under development for both orphan and non-orphan indications with a particular focus on neurological conditions.

GW Pharmaceuticals was founded in 1998 and is listed on the NASDAQ Global Market (GWPH). The company has operations in both the US and the UK.


Dr. Geoffrey Guy
Chairman and Founder
Justin Gover
Chief Executive Officer and Executive Director
Cabot Brown
Non-Executive Director
Thomas Lynch
Non-Executive Director
James Noble
Non-Executive Director (Deputy Chairman)
Catherine Mackey, Ph...
Non-Executive Director
Alicia Secor
Non-Executive Director
Lord William Waldegr...
Non-Executive Director
$ 168.83
Share volume:
52.49 K
Total value:
7.262 M
Market cap:
5.163 B